Vitamin D receptor agonists, cancer and the immune system: an intricate relationship
Luciano Adorini1, Kenn C Daniel, Giuseppe Penna
1BioXell, 20132 Milano, Italy. Luciano.Adorini@bioxell.com
Abstract:
Vitamin D receptor (VDR) agonists can inhibit cell growth, promote apoptosis, and induce differentiation of many cell types, in addition to inhibiting metastasis and angiogenesis, all desirable properties for a drug to control cancer. However, from an immunological perspective, the immunomodulatory properties of VDR agonists are apparently just opposite to the main aims of cancer immunotherapy: boosting the immune response and breaking tumor-related tolerance. While it may be possible to identify VDR agonists with enhanced anti-proliferative/pro-differentiative and reduced immunomodulatory activities as anti-cancer agents, a complementary approach could rely on identifying clinical indications where their systemic immunomodulatory properties could be minimized. Superficial bladder cancer, where treatments are usually administered by vesical instillation, may represent such an indication. We have observed a strong synergism in vitro between calcitriol and doxorubicin or epirubicin in the inhibition of bladder cancer cell proliferation. Thus, calcitriol and doxorubicin or epirubicin in combination may have clinical value in the management of superficial bladder cancer.
Insights
Vitamin D receptor agonists show anti-cancer effects but may hinder immunotherapy. Combining calcitriol with chemotherapy drugs like doxorubicin may be effective for superficial bladder cancer, minimizing systemic immune effects.
Area of Science:
- Oncology
- Immunology
- Pharmacology
Background:
- Vitamin D receptor (VDR) agonists exhibit anti-cancer properties like inhibiting cell growth and promoting apoptosis.
- However, VDR agonists possess immunomodulatory effects that may counteract cancer immunotherapy goals.
- Minimizing systemic immunomodulatory effects of VDR agonists is crucial for their therapeutic application in cancer.
Purpose of the Study:
- To investigate the potential of VDR agonists in managing superficial bladder cancer.
- To explore the synergistic effects of calcitriol (a VDR agonist) with doxorubicin or epirubicin in bladder cancer treatment.
- To identify clinical settings where VDR agonists' immunomodulatory effects can be minimized.
Main Methods:
- In vitro studies were conducted to assess the effects of calcitriol, doxorubicin, and epirubicin on bladder cancer cell proliferation.
- Synergistic interactions between calcitriol and chemotherapeutic agents were evaluated.
Main Results:
- A strong in vitro synergism was observed between calcitriol and doxorubicin or epirubicin in inhibiting bladder cancer cell proliferation.
- These findings suggest a potential for combined therapy in superficial bladder cancer.
Conclusions:
- Calcitriol in combination with doxorubicin or epirubicin demonstrates significant anti-proliferative effects on bladder cancer cells in vitro.
- This combination therapy may offer clinical value for superficial bladder cancer, potentially by localizing treatment and minimizing systemic immunomodulatory effects.
Related Concept Videos
Tumor Immunotherapy
Cancer Vaccines
Cancer vaccines come in two categories: preventive (prophylactic) and treatment (active). Preventive vaccines, such as the Human Papillomavirus (HPV) vaccine, protect against viruses that cause certain...
Psychoneuroimmunology: Diabetes and Cancer
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
Adaptive Mechanisms in Cancer Cells
Some of the advantages that cancer cells have on normal cells include - enhanced ability to divide without terminally differentiating, induce new blood vessel formation,...


